CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma
Article first published online: 18 FEB 2010
Copyright © 2010 John Wiley & Sons A/S
Journal of Cutaneous Pathology
Volume 37, Issue 7, pages 737–743, July 2010
How to Cite
Clarke, L. E., Frauenhoffer, E., Fox, E., Neves, R., Bruggeman, R. D. and Helm, K. F. (2010), CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma. Journal of Cutaneous Pathology, 37: 737–743. doi: 10.1111/j.1600-0560.2010.01532.x
- Issue published online: 18 MAY 2010
- Article first published online: 18 FEB 2010
- Accepted for publication January 12, 2010
CD10 is now commonly used to differentiate atypical fibroxanthoma (AFX) from melanoma, spindle cell and dedifferentiated variants of squamous cell carcinoma and leiomyosarcoma. However, we have encountered CD10-positive tumors that mimicked AFX but proved to be myxofibrosarcomas. The purpose of this study was to evaluate CD10 expression in a wide range of mesenchymal neoplasms that may involve the skin using tissue microarrays. Our results indicate that in addition to AFX, CD10 expression is common in myxofibrosarcomas, undifferentiated pleomorphic sarcomas, dermatofibromas and dermatofibrosarcoma protuberans. Myxofibrosarcomas commonly present in the skin and may be difficult to distinguish from AFX on small biopsies and CD10 positivity may confound the diagnostic difficulty.
Clarke LE, Frauenhoffer E, Fox E, Neves R, Bruggeman RD, Helm KF. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.